中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 5
May  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(5): 952-960

Effect of NOD‑like receptor family pyrin domain containing 3 knockdown on a mouse model of nonalcoholic steatohepatitis induced by high-fat high-carbohydrate diet

DOI: 10.12449/JCH240514
  • 1a.

    Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine Shanghai 201203，China

  • 1b.

    Experimental Center for Science and Technology,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine，Shanghai 201203，China

  • 2.

    Shanghai Key Laboratory of Traditional Chinese Clinical Medicine，Shanghai 201203，China

  • 3.

    Key Laboratory of Liver and Kidney Diseases,Ministry of Education，Shanghai 201203，China

  • 4.

    Baoshan District Hospital of Integrated Traditional Chinese and Western Medicine，Shanghai 201900，China

Research funding:

National Natural Science Foundation of China (82174040);

The Excellent Doctoral Projects in Key Fields of Shanghai University of Traditional Chinese Medicine (2-089);

District level Medical and Health Key Project of Shanghai Baoshan District Science (21-E-63)

More Information
  • Corresponding author: FENG Qin， fengqin@shutcm.edu.cn （ORCID：0000-0002-4641-1636）
  • Received Date: 2023-08-15
  • Accepted Date: 2023-08-31
  • Published Date: 2024-05-25
    Abstract
  •   Objective  To investigate the effect of NOD-like receptor family pyrin domain containing 3 （NLRP3） knockdown on a mouse model of nonalcoholic steatohepatitis （NASH） induced by high-fat high-carbohydrate （HFHC） diet.  Methods  A total of 44 mice were randomly divided into normal diet group （CON group） with 20 mice and HFHC group with 24 mice. At the end of week 14 of modeling， 4 mice were randomly selected from the HFHC group for the pre-experiment of adeno-associated virus （AAV） by tail vein injection， and NLRP3 knockdown was verified after 4 weeks. After NLRP3 knockdown was verified at the end of week 18， the remaining 40 mice were given a single tail vein injection of AAV， and then they were divided into CON+NLRP3 knockdown negative control group （CON+NLRP3-NC group）， CON+NLRP3 knockdown group （CON+NLRP3-KD group）， HFHC+NLRP3-NC group， and HFHC+NLRP3-KD group， with 10 mice in each group. At the end of week 24， the activation of NLRP3 inflammasome was observed； related indicators were measured， including body weight， liver weight， liver index， and glucose metabolism （fasting blood glucose， fasting insulin， and Homeostasis Model Assessment of Insulin Resistance ［HOMA-IR］ index）； the indicators of liver lipid content （liver triglyceride ［TG］ and oil red O staining）， liver inflammation （serum alanine aminotransferase ［ALT］ activity， HE staining， and inflammation-related genes）， and liver fibrosis （Sirius Red staining and fibrosis-related genes） were measured. A one-way analysis of variance was used for comparison of continuous data between multiple groups， and the least significant difference t-test was used for further comparison between two groups.  Results  Compared with the CON+NLRP3-NC group based on the results of Western Blot， the HFHC+NLRP3-NC group had significant increases in the protein expression levels of NLRP3， pro-Caspase1， Caspase1， ASC， and IL-1β， while the HFHC+NLRP3-KD group had significant reductions in these levels （all P<0.05）. The HFHC+NLRP3-NC group showed varying degrees of increase in body weight， liver weight， liver index， and glucose metabolism indicators， while the HFHC+NLRP3-KD group showed significant improvements in these indicators （all P<0.05）. As for hepatic fat deposition， compared with the CON+NLRP3-NC group， the HFHC+NLRP3-NC group had a significant increase in liver TG， with a large number of red lipid droplets shown by oil red O staining， and the HFHC+NLRP3-KD group had significant reductions in liver TG and the number of lipid droplets in the liver （all P<0.01）. In terms of liver inflammation， compared with the CON+NLRP3-NC group， the HFHC+NLRP3-NC group had significant increases in serum ALT， NAFLD activity score， and inflammation-related genes， while the HFHC+NLRP3-KD group had significant reductions in these indicators （all P<0.01）. As for liver fibrosis， compared with the CON+NLRP3-NC group， the HFHC+NLRP3-NC group had significant increases in collagen fiber area and fibrosis-related genes， and the HFHC+NLRP3-KD group had significant reductions in fibrosis-related genes （all P<0.05） and a tendency of reduction in collagen fiber area （P>0.05）.  Conclusion  NLRP3 knockdown can significantly improve hepatic fat deposition and inflammation in a mouse model of HFHC-induced NASH.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64( 1): 73- 84. DOI: 10.1002/hep.28431.
    [2]
    YOUNOSSI Z, ANSTEE QM, MARIETTI M, et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2018, 15( 1): 11- 20. DOI: 10.1038/nrgastro.2017.109.
    [3]
    DAY CP, JAMES OF. Steatohepatitis: A tale of two“hits”?[J]. Gastroenterology, 1998, 114( 4): 842- 845. DOI: 10.1016/s0016-5085(98)70599-2.
    [4]
    PRÓCHNICKI T, MANGAN MS, LATZ E. Recent insights into the molecular mechanisms of the NLRP3 inflammasome activation[J]. F1000Res, 2016, 5: F1000 Faculty Rev-1469. DOI: 10.12688/f1000research.8614.1.
    [5]
    WU XF, ZHANG F, XIONG X, et al. Tetramethylpyrazine reduces inflammation in liver fibrosis and inhibits inflammatory cytokine expression in hepatic stellate cells by modulating NLRP3 inflammasome pathway[J]. IUBMB Life, 2015, 67( 4): 312- 321. DOI: 10.1002/iub.1348.
    [6]
    YANG G, LEE HE, LEE JY. A pharmacological inhibitor of NLRP3 inflammasome prevents non-alcoholic fatty liver disease in a mouse model induced by high fat diet[J]. Sci Rep, 2016, 6: 24399. DOI: 10.1038/srep24399.
    [7]
    WEI Q, ZHU R, ZHU JY, et al. E2-induced activation of the NLRP3 inflammasome triggers pyroptosis and inhibits autophagy in HCC cells[J]. Oncol Res, 2019, 27( 7): 827- 834. DOI: 10.3727/096504018X15462920753012.
    [8]
    WANG L, HAUENSTEIN AV. The NLRP3 inflammasome: Mechanism of action, role in disease and therapies[J]. Mol Aspects Med, 2020, 76: 100889. DOI: 10.1016/j.mam.2020.100889.
    [9]
    CALCAGNO DM, CHU A, GAUL S, et al. NOD-like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH[J]. Hepatology, 2022, 76( 3): 727- 741. DOI: 10.1002/hep.32320.
    [10]
    MRIDHA AR, WREE A, ROBERTSON AAB, et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice[J]. J Hepatol, 2017, 66( 5): 1037- 1046. DOI: 10.1016/j.jhep.2017.01.022.
    [11]
    QU JW, YUAN ZQ, WANG GY, et al. The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice[J]. Int Immunopharmacol, 2019, 70: 147- 155. DOI: 10.1016/j.intimp.2019.02.016.
    [12]
    LATZ E, XIAO TS, STUTZ A. Activation and regulation of the inflammasomes[J]. Nat Rev Immunol, 2013, 13( 6): 397- 411. DOI: 10.1038/nri3452.
    [13]
    NEGRIN KA, ROTH FLACH RJ, DISTEFANO MT, et al. IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis[J]. PLoS One, 2014, 9( 9): e107265. DOI: 10.1371/journal.pone.0107265.
    [14]
    QIN WW, WENG JP. Hepatocyte NLRP3 interacts with PKCε to drive hepatic insulin resistance and steatosis[J]. Sci Bull(Beijing), 2023, 68( 13): 1413- 1429. DOI: 10.1016/j.scib.2023.06.003.
    [15]
    KOHLI R, KIRBY M, XANTHAKOS SA, et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis[J]. Hepatology, 2010, 52( 3): 934- 944. DOI: 10.1002/hep.23797.
    [16]
    KLEINER DE, BRUNT EM, VAN NATTA M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease[J]. Hepatology, 2005, 41( 6): 1313- 1321. DOI: 10.1002/hep.20701.
    [17]
    VANDANMAGSAR B, YOUM YH, RAVUSSIN A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance[J]. Nat Med, 2011, 17( 2): 179- 188. DOI: 10.1038/nm.2279.
    [18]
    HUANG SL, WU YW, ZHAO ZH, et al. A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage[J]. Metabolism, 2021, 120: 154797. DOI: 10.1016/j.metabol.2021.154797.
    [19]
    BOARU SG, BORKHAM-KAMPHORST E, TIHAA L, et al. Expression analysis of inflammasomes in experimental models of inflammatory and fibrotic liver disease[J]. J Inflamm(Lond), 2012, 9( 1): 49. DOI: 10.1186/1476-9255-9-49.
    [20]
    CSAK T, GANZ M, PESPISA J, et al. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells[J]. Hepatology, 2011, 54( 1): 133- 144. DOI: 10.1002/hep.24341.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(8)  / Tables(6)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (263) PDF downloads(39) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return